Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
August 7, 2025
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, everyone, and thank you for being with us today. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Andrew Callos, who serves as EVP and Chief Commercial Officer, will discuss commercial readiness work for aficamten. Fady Malik, our EVP of R&D, will share updates on the clinical development program and medical affairs efforts for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give updates regarding the clinical development program for omecamtiv mecarbil and CK-586, which has been renamed ulacamten. Sung Lee, EVP and Chief Financial Officer, will walk through a financial overview covering the quarter just ended. Then, to wrap up, Robert will offer closing remarks and go over the key milestones we expect for the rest of 2025. I'd like to point out that parts of what we discuss next, including answers we give to questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. The results we actually achieve could differ materially from what those forward-looking statements project. More detail about factors that might cause our actual results to differ materially from what's in these forward-looking statements can be found in our SEC filings, including our current report on our second quarter 2025 financial results furnished to the SEC today on Form 8-K. We take on no obligation to update any forward-looking statements after this call. With that, I'll hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate everyone being with us on today's call. During the opening six months of this year, we've seen steady advancement, since we keep hitting important milestones that move us nearer to achieving our goal — the goal of becoming the top specialty biopharma company centered on muscle, dedicated to substantially bettering patient lives by making our novel therapies available worldwide. In Q2, we shared that the FDA pushed back the PDUFA date for the aficamten NDA, which covers treating patients who have oHCM, to December 26, 2025. Our late-cycle review meeting has consequently been rescheduled for September, which matches the 3-month PDUFA extension. We don't think this schedule affects whether aficamten can be approved, and we're eager for that FDA meeting, which we expect will happen shortly and will shape what we do next. In the interim, every activity anticipated alongside the FDA's continuing review proceeds on schedule; for instance, GCP inspections of clinical trial sites, as well as of Cytokinetics, by FDA have now wrapped up with no observations noted; beyond that, we keep up a productive dialogue with FDA, and we're responding to questions in support of their NDA review. Additionally during the quarter, we held a collaborative meeting with FDA concerning our submitted REMS program after their initial review. Right after that meeting, we moved fast to submit a revised REMS package. And despite the PDUFA date being pushed back, our confidence in aficamten's U.S. regulatory position hasn't wavered — that's because of how strong our clinical data is, the alignment we believe exists around our REMS program, and the ongoing two-way communication we have with the FDA. In the same way, we remain firmly convinced that the data for aficamten supports its chances for FDA approval, its unique benefit-risk and pharmaceutical profile, and a label and risk mitigation profile that could be differentiated as a potential new option for oHCM patients. At the same time, during Q2, regulatory assessments of aficamten were also moving forward in Europe and China. Back in April, the EMA sent us their day 120 set of questions regarding the MAA for aficamten in Europe, and we expect to submit our answers soon, staying within the schedule we worked out with the agency. Reviews by the EMA at both clinical trial locations and at Cytokinetics have wrapped up as well, and the takeaway overall was that our Phase III study was run in keeping with applicable rules and guidance, and that the resulting data can be considered acceptable and reliable. We continue to expect that the EMA could grant approval during the first half of 2026, and once that happens, Germany is the market where we aim to launch first. We've been collaborating tightly with Sanofi, our China partner, to help move the NDA review of aficamten forward with the NMPA, which falls under the accelerated regulatory pathway for innovative therapies. The chance to deliver aficamten to patients in more geographies is something we're excited about, and our expectation remains that potential approval in China could come during this year's second half. Beyond that, during the past several months, our preparations for commercial launch have proceeded with more intensity and a sharper sense of focus, and we're taking advantage of this extra time to strengthen our U.S. commercial launch and operational strategies even further. As Andrew will explain in more detail, among the key areas of progress during the second quarter are bringing on board a top-tier U.S. sales force, refining the treatment experience we offer with patients at the center, and connecting with major payers along with other significant stakeholders. In the quarter, we likewise achieved meaningful strides in the continuing clinical trials program we are running for aficamten. In particular, we reported positive top line results from MAPLE-HCM. We are eager to share more on those results and what they suggest about how standard of care treatment could evolve in oHCM once the primary results are presented at the European Society of Cardiology Congress taking place later this month. We likewise continued our work on ACACIA-HCM, the important Phase III study in nHCM, where patient enrollment is finished and we remain on schedule for the top line data we expect during the first six months of next year. nHCM represents a significant area of unmet need, and it is growing as part of the broader HCM population, with no approved therapies that address the disease's underlying cause. Following what may be the first approval in oHCM, nHCM represents an obvious opening for aficamten and for innovation. Beyond aficamten, in Q2 we continued to move forward with patient enrollment in COMET-HF and in AMBER-HFpEF, our two later-stage clinical trials examining omecamtiv mecarbil and CK-586, which is now called ulacamten, respectively. Each study focuses on a different type of severe heart failure. These initiatives are central to what we're trying to do — deliver novel therapies to people dealing with cardiac muscle dysfunction, and at the same time address the significant gaps that remain in heart failure care as we continue advancing our specialty cardiology franchise. In summary, during the last quarter we made substantial strides on regulatory matters, commercial preparation, and clinical development goals, and that momentum keeps growing as we approach key milestones we expect in the back half of 2025. On that note, I'll turn things over to Andrew now.
Andrew Callos
executiveThank you, Robert. Given the extension to our PDUFA date, we've reworked our timelines and are using that added window to complete the remaining work needed for U.S. commercial launch readiness, while also sharpening how we roll out our promotional campaign and our patient support program. Lately, one major area of emphasis has been bringing our U.S. sales force on board. Following a virtual recruiting event in April that went extremely well, more than 8,800 applications came in, and we went on to build a cardiovascular sales team with substantial experience, with almost every territory now staffed; the extraordinary interest in becoming part of Cytokinetics has given us a deep, seasoned talent pool, which lets us be extremely choosy as we put together a best-in-class sales team. At this point we've brought on sales professionals who already have relationships with cardiologists and bring deep therapeutic and industry expertise, which puts us in position to carry out a launch with real impact. On the whole, our new sales colleagues bring more than 21 years of industry experience and, on average, 14 years of cardiovascular experience. We anticipate having the sales force in place and trained during Q4, so that they're prepared for a U.S. launch of aficamten in early Q1 2026. On top of that, over the quarter we made headway in fine-tuning our distribution network of specialty pharmacies and distributors. That infrastructure is going to matter a great deal in providing a high-quality, patient-centric experience for patients and providers alike. We also moved forward on building our bespoke patient support program. When you put it all together, our aim is to deliver an integrated, straightforward, patient-centric treatment and assistance experience at every touch point, for HCPs and their patients. As we get closer to a possible approval later this year and to commercialization, we stay focused and motivated by the significant unmet need. We think roughly 80% of eligible obstructive HCM patients will be treatment-naive when it comes to a cardiac myosin inhibitor. That means symptomatic oHCM patients who are naive to CMIs and mostly seen in specialty centers for HCM are a starting point for aficamten. Our approach at launch is to grow the market and make sure more cardiologists feel confident with aficamten and more patients can potentially gain from this new therapy. Importantly, based on our market research, close to 80% of HCPs pulled in HCM specialized centers know aficamten on a needed basis, which gives us a solid foundation for initial engagement, from which we expect to build market adoption and extend into community cardiology. More recently, market research findings that incorporated a target product profile based on MAPLE-HCM led to additional support, likely extending prescribing past HCM specialized centers. Our promotional launch campaign for HCPs and patients alike, which is presently undergoing final market research testing and refinement, is built to evolve alongside our market positioning in key areas of differentiation; we believe that because of aficamten's differentiated profile, these messages will land and add to both commercial launch and category preference. Payer engagement also continues to be a priority. During Q2, we kept working to inform payers about what came out of SEQUOIA-HCM, as well as the HCM clinical and economic toll. We also started developing foundational health economics and outcomes research models covering budget impact, cost effectiveness, and cost comparisons, which will serve payer needs in both the U.S. and outside it as we get closer to possible regulatory clearance in major U.S. and EU markets. Turning specifically to Europe, our commercial readiness efforts are advancing substantially. Over Q2, we expanded our EU commercial team and our leadership team, kept preparing dossiers for 2026 submissions to several HTAs, and moved launch readiness forward in numerous countries, centering on what could be our first commercial launch, in Germany, during the first half of 2026. All told, I'm happy with how we're positioned ahead of a possible aficamten approval. Having said that, I'll hand the call to Fady so he can discuss our continuing clinical trials program and medical affair work for aficamten.
Fady Malik
executiveThank you, Andrew. We were happy to share that during Q2, top line results came in positive from MAPLE-HCM, showing a statistically significant gain in peak oxygen uptake from baseline through week 24 for aficamten when set against the standard of care beta blocker, metoprolol. The safety and tolerability profile for aficamten likewise came out favorable relative to metoprolol. MAPLE-HCM stands alone as the trial that puts a cardiac myosin inhibitor head-to-head against the long-standing standard of care therapeutic approach of beta-adrenergic receptor blockade. As we announced not long ago, the complete findings from MAPLE-HCM are set for a hotline session on Saturday, August 30, at the European Society of Cardiology Congress in Madrid later this month. There's also a prespecified analysis from the trial that looks at how aficamten compares with metoprolol in terms of cardiac structure and function, and that one is set to be presented on Sunday, August 31. Until that point, we aren't able to say anything more about the top line results, though we're looking forward to providing much greater detail in just a few weeks. So why do these data carry weight? MAPLE-HCM addresses not just the treatment effect and safety profile of aficamten when compared with metoprolol, but additionally how metoprolol on its own affects exercise performance, gradients, symptoms and biomarkers. Once the results are presented at ESC, as you'll see, we think these findings may end up being incorporated into treatment guidelines and could drive modifications to standard of care treatment algorithms in obstructive HCM. Additionally, we plan to present further findings and evaluations of interest during ESC. These include a late-breaking clinical trial session addressing how often atrial fibrillation occurs and what effect it has among oHCM patients, drawing on pooled data from REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM. Whether cardiac myosin inhibitors can be used safely has made atrial fibrillation a growing subject of discussion, yet uncertainty remains over whether these atrial fibrillation adverse events stem from the disease itself or from the treatment. In our previously completed aficamten trials, as we have noted before, the rates of atrial fibrillation proved identical for placebo and aficamten. Furthermore, within FOREST-HCM, our open-label extension study, the frequency continues to match what historical data would predict. We're looking forward to presenting this information, which in our view supports a steady safety picture for aficamten among individuals living with oHCM. While at ESC, there will also be an oral session covering longer-term tracking of people who received aficamten in FOREST-HCM, incorporating as much as three years of accumulated findings in a refreshed pooled safety review spanning the aficamten clinical research effort in oHCM, which includes MAPLE-HCM. Considered overall, we anticipate that what gets shared at ESC will considerably broaden understanding of aficamten's safety along with its effects over a longer horizon in those with oHCM. Now shifting to nonobstructive HCM: across the quarter, our work continued on ACACIA-HCM, a pivotal Phase III study of aficamten for nonobstructive HCM. Like we said before, the ACACIA trial wrapped up getting patients signed up sooner than we'd planned earlier in the year, and actually went past our initial goal for randomization — randomizing 516 participants in all. During the second quarter, we reviewed the updated safety data from ACACIA-HCM alongside the Data Monitoring Committee. They advised that the trial ought to continue without any changes to the protocol or how it's run. We expect to be able to share top line results for ACACIA-HCM's primary cohort, excluding Japan, sometime in the first half of 2026. When it comes to Japan, we dosed our first patient in that country's cohort of ACACIA-HCM not long ago, and Bayer, our partner, began accepting enrollment for CAMELLIA-HCM, a Phase III clinical trial involving Japanese patients who have obstructive HCM — a study meant to back possible marketing authorization there. Regarding the aficamten trials that are underway, we advanced enrollment in CEDAR-HCM during Q2; that trial is assessing aficamten in pediatric obstructive HCM. Enrollment of the adolescent cohort in that study is still expected to wrap up in the second half of this year. Last, beyond the strides made in our clinical development programs, our field medical affairs teams took part in close to 600 U.S. HCP interactions during the quarter, among them more than 200 HCM KOLs and more than 50 European KOLs. The team also showed up at major payer conferences such as Asembia, AMCP and regional AMCP meetings, in order to engage actively with national and regional payers. I'll now hand things over to Stuart for updates on the rest of our late-stage development programs.
Stuart Kupfer
executiveThank you, Fady. To begin, we kept up our launch-related work and kept bringing patients into COMET-HF, the confirmatory Phase III study of omecamtiv mecarbil in people who have symptomatic heart failure along with a severely reduced ejection fraction below 30%. Over the quarter, the first of our sites in Europe began operating, and we kept adding activated sites across the U.S., and both of those things are fueling momentum in enrollment. Our plan is to keep enrolling COMET-HF all through this year and to finish enrollment in 2026. Next, as we shared in today's press release, the World Health Organization's INN Program granted approval for ulacamten as a nonproprietary name for CK-586. In the second quarter, we kept running AMBER-HFpEF, the Phase II study of ulacamten in patients who have symptomatic heart failure with preserved ejection fraction of at least 60%. The first cohort is making headway in enrollment, and we're happy with how we've done at bringing new clinical trial sites online and at getting investigators involved in this important trial. On the whole, we're pleased with how both of these later-stage pipeline programs are proceeding in the clinic, since they stand as the next strategic pillars for growing our specialty cardiology franchise. Even with all the strides made in heart failure care over the years, a sizable unmet need remains throughout the disease spectrum, and we think our potential medicines could make a difference there; so with that, I'll hand things over to Sung.
Sung Lee
executiveThanks, Stuart. We're happy to share the financial results for our second quarter of 2025. Let's begin with the balance sheet. At the close of the second quarter, we held roughly $1.04 billion in cash, cash equivalents and investments, versus $1.09 billion at the close of the first quarter of 2025. During the second quarter, we exercised our option on the Tranche 4 loan from Royalty Pharma, which brought in proceeds of $75 million. We hold an option to draw $100 million under the Tranche 5 loan before November 25th of this year. R&D expenses came to $112.6 million in the second quarter, up from $79.6 million in the same period of 2024. That rise was mainly driven by moving our clinical trials forward, greater personnel-related costs and medical affairs-related activities. G&A expenses for the second quarter of 2025 totaled $65.7 million, versus $50.8 million in the same period of 2024. That increase largely reflects investments in commercial readiness and greater personnel-related costs. Our net loss for the second quarter of 2025 was $134.4 million, or $1.12 per share, compared with a net loss of $143.3 million, or $1.31 per share, in the same period of 2024. Now to our financial guidance. We are keeping our full year 2025 financial guidance unchanged, with GAAP operating expense projected to land between $670 million and $710 million. Stock-based compensation included in GAAP operating expense should come in between $110 million and $120 million. If you strip stock-based compensation out of GAAP operating expense, that gives a range of $550 million to $600 million. As we get closer to the PDUFA date for aficamten, we'll keep watching how quickly we're making commercial readiness investments and will update you as appropriate; given our current balance sheet and our ability to access additional capital, we're well positioned to fund a potential launch of aficamten in the U.S. later this year and to keep advancing our pipeline. With that, I'll turn it back over to Robert.
Robert Blum
executiveThanks, Sung. As we close out the first half of 2025, I feel good about our position and what we've accomplished, especially with such an important second half ahead of us. We're approaching a pivotal moment — one more than a quarter-century in the making — and our company stands right on the edge of a period of dramatic growth. That achievement reflects many years of scientific breakthroughs, deliberate spending on research and development, and an unwavering dedication to bringing potentially valuable treatments to the patients who need them. All of this depends on the commitment of our teams throughout the company, whose relentless efforts are driving us toward these milestones we've awaited for so long. We've got a solid base, a well-defined direction, and the right team assembled, which puts us in position to create meaningful value for both patients and shareholders, opening the next phase of growth as a fully integrated, high-impact specialty biopharma leader. Let me now walk through the milestones ahead. On aficamten, we plan to push forward with NDA review work alongside FDA to back the potential U.S. If aficamten gets the green light during this year's back half, our plans involve pushing forward with go-to-market strategies and keeping launch preparations moving in the United States throughout that same period. In Germany, go-to-market planning should carry on, and across Europe we'll broaden our commercial readiness work during 2025, all of which sets us up for a possible EMA approval in the opening six months of 2026. Working alongside Sanofi is something we anticipate doing to help secure aficamten's potential clearance in China, which hinges on the NMPA giving its okay. Also coming later this month at ESC: primary results from MAPLE-HCM, which we intend to share. Looking ahead, we anticipate sharing topline data from ACACIA-HCM's primary cohort during the first six months of 2026, and we'll keep adding patients to that study's Japan cohort over the course of 2025. Enrollment for the adolescent group within CEDAR-HCM should wrap up in the latter portion of this year. Turning to omecamtiv mecarbil, our plan is to keep enrolling patients in COMET-HF through 2025, which would allow us to finish enrollment in 2026. As for ulacamten, we aim to finish signing up the initial two patient groups in AMBER-HFpEF during this year's second half. Lastly, on the preclinical and research side, we intend to carry on our existing preclinical work and research efforts aimed at further programs centered on muscle biology. Operator, at this point we're ready to take questions from the line.
Gena Wang
analystI actually have a lot, all right, but I'll keep it to just one, and it's about the ESC update. You mentioned that the MAPLE data might potentially lead to a guideline change. Could you say a bit more about what size of benefit you're expecting — which key data points ought to be our focus? And what level of benefit would make a payer or a physician willing to use it first-line, or to switch those patients off a beta blocker and onto aficamten?
Robert Blum
executiveClearly, answering that isn't easy before you have the data in hand that we do, but I'll let Fady give it his best shot.
Fady Malik
executiveCorrect. In my view, the data — this ranks among the very few head-to-head efficacy studies carried out within cardiology. And once those data are shown, they will reveal not just how the 2 differ, but also the absolute advantage that each of the 2 drugs delivers on its own relative to baseline at the point these patients begin therapy. At present, cardiac myosin inhibitors are regarded as a final option once all other treatments have failed; and I believe that after we see what MAPLE-HCM shows, that discussion will be taken up again, and ideally guidelines too will be revised so they capture what we have already reported regarding aficamten's superiority over metoprolol and exercise tolerance. Still, I think we will simply need to wait until the data are available before we can say more on that.
Akash Tewari
analystSo it seems more and more probable that the Camzyos ODYSSEY results will come out at ESC. Which 2 or 3 items in those results ought investors be watching that would back the team's theory that ACACIA will work where Camzyos did not, and would also back a distinct exposure response relationship among this population?
Robert Blum
executiveYes. I'll give that a try, and perhaps ask Fady to chime in. I believe it matters a great deal to separate what stems from how a clinical trial is run from what stems from a possible mechanism of action as it carries over to that patient population. Obviously, with ACACIA, we adopted what we regard as an optimized dosing regimen that a Phase II study had confirmed, and carried it into a Phase III trial in which we chose to move forward without changing a lot of other elements. We adopted a dose optimization regimen. We adopted a population. We concentrated on centers where experience already existed with us; and clearly, here at Cytokinetics, we have a skilled group of HCM experts, trained both in academia and in industry, so as to be able to guarantee that patients satisfied the criteria. The sorts of items we'll be watching relate, from a study conduct and operations angle, to how much change there might have been between the Phase II and the Phase III study for mavacamten, and how much that might have influenced the Phase III outcome, versus where we think our focus has stayed quite linear as we moved from one to the next. Fady, anything you'd like to add?
Fady Malik
executiveOne more thing I’d mention: once the ODYSSEY results are available — and we haven’t laid eyes on them yet, nor have we — the key issue is going to be whether the study missed its primary endpoint owing to particular characteristics of mavacamten or the way the trial was run, as opposed to the mechanism of action. And ultimately, I believe that is what will give people some reassurance about ACACIA’s chances of succeeding. Still, as Robert said, our confidence in ACACIA succeeding is strong, simply because of how robust the Phase II data we produced were, and because ACACIA is being run in a way that closely matched how we ran Phase II.
Tessa Romero
analystSo for aficamten in obstructive HCM, what would the ideal label look like here? And Robert, could you go a bit deeper on whatever details you're able to share about the updated REMS that you seem to have filed compared with the first version? And how do those changes line up with what you expect for a differentiated REMS?
Robert Blum
executiveYes; so given that our discussions with FDA are still going on, there's a great deal in that question I'm not able to unpack; but what I believe I can say is that the ideal label for aficamten is one consistent with its engineered properties and the manner in which it has been studied. And we believe both of those enable differentiation in a way that could be supportive of our expected profile; we built into aficamten features Fady has frequently described, and we've conducted studies of aficamten that we believe shed further light on how those features read on benefit risk. And the data from our Phase II and Phase III studies and also as further substantiated in the open-label extension support what we've argued would be a potentially differentiated program in the clinical setting for patients, but also for physicians. I might ask Andrew, our Chief Commercial Officer, to speak to how his market research has been pointing to the unmet need and where we believe a differentiated label could support our expectations and aspirations.
Andrew Callos
executiveAbsolutely, Robert. So I believe you made the point nicely that a label with differentiation would genuinely mirror what came out of the clinical trial along with aficamten's characteristics. When it comes to market research, what our studies have shown, I'd say, is that should the REMS and the label genuinely capture the properties and the study, then we'd anticipate solid uptake at the centers of excellence, which is where the bulk of prescribing happens today. As I noted earlier in my remarks, there are already a great many physicians at those centers — over 80% — who know about aficamten. So awareness is extremely high, and that's before we even reach the market. That growth into community cardiology and general cardiology, backed by that differentiation and further backed by MAPLE — that's what our market research is showing, pointing toward a preference here, even after adjusting for overstatement in our market research. So in the end, we have to wait and see how that label and REMS come out from the FDA, but based on those comments, we're feeling quite bullish.
Salim Syed
analystLet me ask about the oHCM late-cycle meeting; Robert, what specifically do you intend to find out or talk about at that September late-cycle meeting? Also, could you remind us what portion of the REMS negotiation actually takes place after the late-cycle meeting, during the label negotiations themselves?
Robert Blum
executiveSalim, those are excellent questions. I can't guarantee my answers will fully satisfy you, because Cytokinetics and FDA have already covered so much ground. My hope is that when the late-cycle meeting arrives, we find out that all our assumptions remain on track toward possible approval, and that nothing new is brought into the picture. As for what has taken place so far, we think we've handled those items with little divergence or gap between what FDA may want and what we could supply as supporting evidence. Take the REMS as an example. Right after we submitted one, FDA and Cytokinetics held a meeting to talk it over. That discussion proved highly productive. We managed to make revisions very fast that we believe answered FDA's concerns; so at a late-cycle meeting, my hope is that we receive confirmation everything is cleared to move forward; though a REMS dialogue like this is somewhat uncharted, and it's possible we'll find out something new. I hope that won't happen, but we're strongly of the view that we and FDA are in agreement about what it wants. And on that note, Cytokinetics, our colleagues here, anticipated this really well, so that once FDA told us it did in fact want a REMS, we were prepared to submit one immediately after. So in that sense, to respond to your question, what I'd like to find out at the late-cycle meeting is that we're moving ahead to final label discussions and that we don't expect any other new developments.
Cory Kasimov
analystSo I'd like to ask — let's return to ACACIA, and I'm wondering whether you could take us through the ways drug interruption and discontinuation protocols are different from those in ODYSSEY. What I'm especially interested in, I suppose, is how ACACIA is not the same as the 4-week dose interruption that has to happen when LVF falls under 50%, which was what occurred in ODYSSEY. And perhaps you could flag any other notable design differences between the 2 studies that you might call out.
Robert Blum
executiveYes. Well, the design differences are significant. It would appear much like there are design differences in other studies. And again, whether ACACIA is conducted in accordance with that design may ultimately prove to matter. So now that we have ODYSSEY as published in terms of the design, and we know what we're doing with ACACIA, I'll ask Fady to comment, and I think it's good to highlight some of those distinctions.
Fady Malik
executiveRight, Cory, regarding the situation where LVEF drops under 50%: in the nonobstructive case, there's no left ventricular outflow tract gradient there to cushion you against that. So really — the way I frame what we're doing in oHCM is that we're putting up with the lowest dose that works, while in nHCM we're putting up with the highest dose a patient can take, and those are very different ideas. Consequently, when EF is under 50%, it's good that with ACACIA, as long as EF stays over 40% in most cases, patients are able to simply reduce the drug dose. Treatment isn't stopped at all. Should EF fall below 40%, drug is halted for roughly 1 week, then restarted afterward at a reduced dose. That's — so that marks a meaningful contrast, I'd say, versus ODYSSEY, where drug must be paused for 4 weeks before restarting, causing considerable upheaval, so to speak, in the — in the treatment. A further piece of this: every dose got tested, so to speak, during Phase II — 5, 10, 15, and 20. And mostly the 15- and 20-milligram strengths ended up being used most often. As we're aware, in ODYSSEY, BMS brought in 1-milligram and 2.5-milligram doses. Patients were able to titrate down to those. And in the end, whether the dose density, so to speak, sits within the range recognized as — as potentially efficacious, we simply don't know. Meanwhile, in ACACIA, the doses being tested are ones where at minimum we think we observed meaningful clinical benefit during Phase II and are now attempting to duplicate in Phase III. So on the dosing question, those represent the key contrasts when EF is under 50%. Certain entry criteria differ too, around thresholds, the upper limit for peak VO2 or NT-proBNP. Our team here knows HCM deeply and genuinely reviews each patient echo submitted into the study. So we're attempting to maximize, so to speak, how appropriate the patient population is; hence a range of differences exists there. And in the end, once ODYSSEY data arrive, we can ask ourselves how — which among them could matter for ACACIA's success going forward.
Robert Blum
executiveEmma here, filling in for Yas. So, I suppose the first thing is: what do you anticipate regarding possible REMS variations between the U.S. and EU, and what would those mean?
Robert Blum
executiveWell, given that Europe doesn't have that same type of REMS framework, it would be handled through different channels instead. Taken as a whole, I doubt there will be all that many distinctions, especially since our study was international and what we're hearing from FDA and EMA is following a very similar path. So even though Europe lacks a formal REMS, we should expect — and we are expecting — labels that are comprehensive when it comes to risk mitigation, drug-drug interaction, pharmacology, and other aspects like dosing and indication, and there will be far more overlap than there will be divergence.
Ike Lee
analystIke Lee here, filling in for David Lebowitz. I'd like to inquire about the bigger opportunity in the market for nonobstructive HCM, which everyone recognizes exists. From what we understand, once that launch happens, you'll presumably have to connect with additional community physicians; with that in mind, if and when that moment arrives, how much bigger do you expect your sales force will need to be?
Robert Blum
executiveYeah. Maybe I'll turn to Fady, and possibly Stuart if he'd like to chime in, regarding the way nHCM gets treated and in what settings, and then perhaps ask Andrew as well for his viewpoint on this, particularly since it could eventually have a bearing on how large our commercial team ends up being.
Fady Malik
executiveAbsolutely. nHCM is genuinely just the visible portion of a much larger problem. What happens is that the nHCM patients showing up in clinics tend to be the sicker ones — the ones whose echocardiograms make the condition plain to see. Diagnosing this disease, though, is no easy task. Stuart, perhaps you could weigh in on the obstacles involved in spotting it, and on why its true frequency across the general population may be much greater than we currently appreciate.
Stuart Kupfer
executiveOkay, so, as you pointed out earlier, obviously individuals without obstruction show no gradients, which is one major factor that complicates making a diagnosis. Then there are several characteristics that can cause HCM patients to resemble those who have heart failure with preserved ejection fraction, so it really requires some careful differentiation to pick out these patients rather than just assuming they have heart failure with preserved ejection fraction. Another key point, I think, is that in contrast to obstructive HCM, for which more specific guidelines exist regarding treatments that are available—and we could argue about how strong the evidence is behind those treatments—there is even less direction when it comes to managing nonobstructive HCM. So the unmet need is plainly even greater, and perhaps Andrew could speak to that.
Andrew Callos
executiveYeah, so if you compare nHCM with oHCM, the list of physicians we'd initially go after wouldn't change at all. That means we don't anticipate growing our field team when nHCM launches, assuming ACACIA reads out positively and the regulators give it the green light. Our approach to identifying and evaluating the cardiologists involved in HCM — for both diagnosing and treating it — relies on claims data along with ICD-10 codes; and the doctors our reps visit for oHCM handle nHCM as well as oHCM. There's also substantial overlap with those subspecialists who are advanced heart failure cardiologists and who also manage HCM. So our attention sits on the roughly 10,000 who account for 80% of HCM diagnosis and treatment. Should we gain additional understanding of nHCM — and at present, the oHCM patient population and the nHCM population are split roughly 50 to 50 in size — then we would definitely scale up the field force if necessary. At launch, though, that isn't something we anticipate.
Yasmeen Rahimi
analystKhalil here, filling in for Paul. There have been quite a few questions regarding regulatory interactions, so I'll direct mine toward aficamten and the commercial side. With some other cardiology launches happening lately, attention has turned toward patient access. We're wondering if you've put any strategies in place that would set you apart from Camzyos when it comes to patient access—whether for commercial-age patients or those on Medicare. That would be useful for us.
Robert Blum
executiveSure. This is something Cytokinetics has been extremely focused on for a good while now, and Andrew and his highly skilled team have been working very diligently on it from a market development perspective and in terms of what we'll see with aficamten. So I'll hand it over to him for his thoughts.
Andrew Callos
executiveAbsolutely. As Robert mentioned earlier, our field-based account managers have been in discussions with payers for a good while now. Every significant payer has been reached or engaged by us. On the commercial side, we anticipate achieving a level of access parity. Regarding Medicare, we likewise expect parity and access there. So the approach truly centers on securing equivalent access, with the real differentiators being support and differentiation itself. Turning to patient support, we're building our program around this specific patient group, the journey they undertake, and the assistance required, REMS included. As for the types of programs we'll provide, for qualifying patients—those with commercial coverage—there will be co-pay help, and for people who lack insurance or are underinsured, we'll offer patient assistance programs. So I believe you'll see that the patient support offerings, the access, and the affordability are all aimed at matching mava's position, or perhaps even standing slightly better. The differentiation, once again, will center on the clinical data, the REMS, and what patients experience.
Jason Butler
analystI suppose this builds on what we were just discussing. Regarding your growth into Europe and the commercial efforts underway there, could you perhaps describe a few of the ways the prep work for the European launch is similar to what's needed elsewhere, and a few of the ways it differs?
Robert Blum
executiveSure. Keep in mind that our priority sits with the U.S. launch, though over in Europe we are proceeding with careful, intentional measures to get ready for what we hope will be a launch during the first half of the year, starting with Germany and expanding from there. So Andrew, who heads up those efforts alongside teammates already based in Europe, is evaluating things market by market, and figuring out where reimbursement will serve as the trigger for a meaningful commitment of capital. That said, I'll let him go into greater depth about how we're approaching this.
Andrew Callos
executiveOkay, the main point here is pretty clear: in Europe, the rollout happens nation by nation. For most of Europe you obtain EMA authorization — leaving out Switzerland and the U.K. for the time being — and because it's an EMA approval, the majority of European nations grant it uniformly. After that, you must secure reimbursement separately in each country. In Germany, pricing is free for a period of 6 months while negotiations over the price are underway. That's a major distinction when it comes to each individual launch, and the government is the primary payer. You must complete health technology assessments, set pricing and reimbursement, and only then do you launch. So past the regulatory hurdle, there's a second hurdle: reimbursement. Another important distinction, I'd say, is that after reimbursement happens, prescribing tends to concentrate in specialized centers of excellence — hospital-focused cardiology. That makes prescribing in Europe generally narrower and more concentrated than what you see in the U.S. And as Robert mentioned, there's no REMS program in Europe. Risk management is generally addressed through labeling. So those, I'd say, are the main distinctions. That said, when it comes to how aficamten is differentiated based on the clinical trial and the way we convey that, once we secure access, it will be quite comparable — though again, this plays out nation by nation. The bulk of our spending doesn't happen country by country until reimbursement is in place; so we've gated it, and we're building Europe gradually, whereas the U.S. will hopefully launch all at once toward the end of this year or in early next year. Europe's launch will really unfold across roughly 2 to 2.5 years, depending on the timing of reimbursement.
Robert Blum
executiveWe've tried to learn from how other businesses have entered Europe—a few that managed it well, though honestly, most did not. That's the reason Sung, alongside Andrew and other members of our leadership team, is pursuing a highly disciplined and intentional strategy regarding Europe, and doing it in a way that's shaped by milestones aimed at reducing risk.
Jim Condulis
analystCongratulations on the strides you've made. Perhaps a brief question regarding HFpEF. We're just interested because those results should arrive around the beginning of next year, and I'm wondering whether you could outline what would constitute a favorable outcome. In that same vein, I'd like to know how critical you believe a Phase III win in nonobstructive disease is for validating any early signs, particularly since systolic dysfunction underlies both conditions.
Robert Blum
executiveSure. Those are solid questions, particularly the connection between our nHCM efforts and what that might tell us about HFpEF. I'm going to invite Fady and Stuart to weigh in as well.
Fady Malik
executiveRight, so I'd say the conversations we had regarding ACACIA before give a pretty solid picture of what we expect — or at least hope — to show up with AMBER. And maybe I'll turn it over to Stuart to lay out how these two conditions line up and why we believe each will strengthen the other.
Stuart Kupfer
executiveYes. I appreciate that question. As Fady pointed out, patients with nonobstructive HCM do provide insight into the possible advantages for those who have HFpEF along with hypercontractility. The endpoints we are assessing in our Phase II AMBER-HFpEF study will reveal the potential benefit. We are assessing symptomatic improvement, examining measures such as KCCQ, NYHA Class, seeking betterment, meaning gains in symptoms, cardiac biomarkers including NT-proBNP and troponin. And naturally, we are assessing echocardiographic parameters, seeking possible advantage regarding diastolic function; all of these will feed into the profile, the potential benefit that will guide whether we advance to Phase III and determine which dose or doses will yield a favorable benefit risk profile. So once more, we take encouragement from what we saw with nonobstructive HCM and the benefit — with advantages of aficamten in the Phase II REDWOOD trial and the continuing cohort that has been assessed in FOREST, our open-label extension. So those are a few of the key findings we will be seeking, along with safety and tolerability.
Leonid Timashev
analystI'd like to ask, as you get closer to commercialization, what's your thinking on the message you'll lead with in HCM? What I'm really trying to get at is this: what do you believe truly fuels enthusiasm among physicians and patients to use the drug? And is it gradient, which can be checked easily? Is it the symptomatic benefits? Is it cardiac function? You've got lots of data spanning lots of these endpoints and, clearly, possible convenience advantages. So what's the messaging you plan to lead with in order to drive use?
Robert Blum
executiveYes. I think you can probably understand that an earnings call isn't the place where we'll be sharing our messaging and positioning with any kind of specifics; instead, you should expect that we'll want to see the label, and in the end, we'll promote to label in ways we believe will benefit adoption of aficamten. But as we've talked about in how we designed aficamten and how we studied it, we do believe there are high levels of differentiation. And it would be reasonable, since this is a next cardiac myosin inhibitor, for us to want to focus on how we might grow the category and grow preferential share of the category for the benefit of more patients, more physicians comfortable with cardiac myosin inhibitors. So with that as a bit of a backdrop, maybe I'll ask Andrew whether there's anything further he'd like to add.
Andrew Callos
executiveRight. So, on the point you raised, we won't be sharing what our messaging will be. But broadly speaking, after FDA approval happens, what physicians truly want is to grasp and take the lead on the efficacy piece, how safety balances against that efficacy, and then, in this case, the REMS as well. So we'll make the differentiation clear when we communicate. We think we stand apart in every one of those areas, plus we have a highly, highly differentiated positioning, but you'll need to wait until our approval and launch, and until we have our label, before any of that is revealed. Thanks for asking.
Paul Choi
analystAlex here, filling in for Kripa. Since China could potentially be the first market where we get approval, could you take us back through how that market works and what sort of revenue rhythm we should anticipate over the next few quarters?
Robert Blum
executiveSure. So it's a bit of an unusual set of circumstances, right, that an approval in China might come through ahead of one in the United States. There is precedent for it, though such cases are rare. That being said, we're doing this work alongside Sanofi, our partner. And perhaps I'll turn it over to Andrew, who is among the leaders of that collaboration, to address your question.
Andrew Callos
executiveYou asking about market sizing and revenue. So is that right?
Kripa Devarakonda
analystYes. And also, what pace of adoption should we anticipate in that market?
Andrew Callos
executiveSo, as in the U.S., aficamten would enter China as the second product on the market. Similar to Europe, you must secure NRDL listing — national reimbursed drug listing in China. That happens annually, and filing must be completed by the end of June of a given year for reimbursement to begin the following January. So, in the initial period, reimbursement would likely come through the cash-paying market, unlike, say, mava, which has NRDL. So my expectation is that uptake would be slow initially, but it's a large market, as you can imagine. More than 350,000 patients are highly concentrated into roughly 1,300 hospitals. Obviously, we have a very sophisticated multinational partner who knows that market extremely well; so I won't comment on the phasing, but I would only say that once reimbursement occurs, I would expect an acceleration follow that national drug reimbursement. Hopefully, that answers your question.
Analyst
analystYes. Congrats on the progress.
Andrew Callos
executiveThank you.
Joe Pantginis
analystTo start, maybe this one's for Andrew — while you're getting everything ready on the broad commercial side, which pieces do you see as things you have to put in place even if they may not ultimately be necessary, just going through the steps based on however a potential REMS might or might not turn out? And then, a second one — for Stuart, when you look at COMET, given how much experience the company has, and very broad experience at that, with omecamtiv over the long term, how would you describe the enthusiasm at the sites when it comes to enrollment compared with all the other studies of omecamtiv?
Robert Blum
executiveSo that first question was a complicated one. I'm trying to make sure I've got it right, Joe. What you're asking is about the types of things we've gotten ready for that we may not wind up needing to do. Is that what I heard?
Joe Pantginis
analystRight, that depends on whether REMS ends up being required or not.
Robert Blum
executiveYeah, so we have a fairly clear picture of how things are developing. And honestly, it lines up well with the 3 meetings we held with FDA prior to filing the NDA, though as you recall, we didn't initially file with a REMS, we had already foreseen what we believed FDA would care about, and we built that into the label. Then FDA came back and said it would actually want a REMS. So we were already set up to carry that out through a REMS; so I'm not sure there's much gap between what we anticipated and where things stand, such that we ended up having to put together something that might not matter. I believe we have a fairly solid sense of where this is headed. As for your other question, perhaps I'll have Stuart weigh in on how much investigator interest there is in COMET.
Stuart Kupfer
executiveAbsolutely. I appreciate it. The key takeaway here is that COMET has drawn a great deal of attention, and that makes us quite happy, for a few different reasons. First, there's a growing understanding of just how significant the unmet need is among these heart failure patients whose ejection fraction is severely reduced; prior to this, they truly lacked medical choices as they progressed toward end-stage heart failure. As a result, they see omecamtiv mecarbil as a possible medical pathway that could prevent that destiny. Next, they know full well about what GALACTIC showed, and that was, naturally, a trial with positive findings; moreover, among the subgroup we are now focusing on in COMET, the degree of therapeutic advantage was substantial, with a decrease in risk for the heart failure outcome. Thus, there is a sense that given how large the sample size was for that subgroup of patients, along with what we saw in GALACTIC, the likelihood of success is strong. And finally, I believe they are quite happy that we are conducting a highly efficient study that places limited demands on investigators and the people who work with them. Consequently, from an operational standpoint, carrying it out will be simpler. All things considered, there is considerable excitement surrounding COMET.
Jason Zemansky
analystThis is Jackie calling in for Jason. Congratulations on the progress. Now that you've had a chance to review additional MAPLE data, could you share your thoughts regarding first-line use? In your view, how likely are prescribers and payers to embrace it? Also, how much time do you expect will pass before we see meaningful uptake within this segment of the market?
Robert Blum
executiveCertainly. I'll begin, and I believe both Fady and Andrew can weigh in from their own perspectives. What I can tell you is that we ran a head-to-head trial of aficamten against metoprolol. I do think it will provoke some surprise regarding what currently stands as guideline-directed first-line therapy. Perhaps that shouldn't come as too much of a shock looking back, since those guidelines were drafted without any randomized controlled study of metoprolol in this patient population. So we're adding to a body of evidence that simply wasn't there previously. Having accomplished that, we do believe aficamten — and once you review the results, you may see why we hold this view — ought to be included in discussions about which medicines to select, and in what sequence, when treating these patients. Admittedly, metoprolol is a generic product, and there is extensive experience with beta blockers. Even so, I do believe that, in Cytokinetics fashion, we are conducting rigorous clinical research to shape guidelines, and hopefully the guidelines will account for how robustly the study was carried out and how reliable the results are. With that, I'll turn it over to Fady to address this, and perhaps Andrew as well, if he'd like to comment on how this might eventually be reflected in guidelines and over what period of time, and how that could influence adoption.
Fady Malik
executiveYeah. I mean, my sense is that displacing beta blockers from their position as the first treatment option is going to require some time, because of how the costs differ. That said, a trial such as MAPLE-HCM, I believe, will help enable a shift to happen sooner, and with any luck, push aficamten higher up in the guidelines. So rather than being viewed as the final option prior to surgery, it would be regarded as equal to the other therapies doctors might choose; and thus, when a patient has only a small amount of improvement, they're aware there's another option they can switch to sooner. As more time passes, our hope is to generate data showing that aficamten does things past simply easing symptoms and improving function — things other therapies cannot do — since aficamten goes after the disease's underlying pathway; because of that, at some point we might demonstrate that we slow how the disease progresses. And at that point, which therapy to begin with, I think, turns into a far bigger question. So I'd say this marks the start of a longer stretch, in a sense, when it comes to altering the standard of care for this disease.
Andrew Callos
executiveYeah, so what we're looking at is that during the initial couple of years following the launch, first-line treatment probably won't happen, and that's largely due to payers. Robert brought up that beta blockers, of course, are generic. What we do anticipate, though, is that a greater number of patients will be taking aficamten compared to what would have happened absent MAPLE. We anticipate seeing faster adoption of adding aficamten on top of a beta blocker, and perhaps gradually tapering patients off the beta blocker once they've started. So those are the sorts of patterns I believe you'll observe across those first few years. Should guidelines get revised and aficamten becomes incorporated into first-line therapy, then as usage widens, first-line treatment might become a reality. But once more, my sense is that's a number of years away. Appreciate the question.
Mayank Mamtani
analystThis is William calling in for Mayank. I'd like to return to ACACIA for a moment. So far today, your emphasis has largely been on ODYSSEY and that Phase II to Phase III shift, and how it backs up possible favorable findings once that data comes out next year. That said, I'm also wondering about how fresh results from the MAPLE study, plus earlier data from SEQUOIA, might bolster ACACIA — and which particular endpoints could be called out to reinforce those arguments? Also, regarding REMS, in what way ought we to interpret REMS for oHCM as it relates to non-obstructive HCM? Should we assume these would be more or less identical, or possibly different simply because of the profiles involved?
Robert Blum
executiveYes. What you're doing is asking us to guess about certain matters that sit quite a distance ahead. And clearly, claims aren't something we can weigh; however, MAPLE was run in an oHCM population where echoes give a great deal of guidance on how dosing gets titrated. ACACIA takes place without that, in a population that's quite distinct. So I'll turn it over to Fady and Stuart for their thoughts, though I can say right now that in our view, not much will carry over between the two. Fady?
Fady Malik
executiveYeah. I believe your question was whether anything from MAPLE or SEQUOIA has taught us something that could shed light on ACACIA. Well, we have already released SEQUOIA findings showing how aficamten enhances diastolic function — the heart's relaxation — and that is likely the main pathway through which nHCM patients gain therapeutic benefit, given that they lack a gradient to bring down. In the same way, at ESC you will see MAPLE data on diastolic function; it forms part of that late breaker I mentioned before; so I think these two datasets together will make clear that a meaningful pharmacologic effect exists that we believe influences how the heart works in nHCM. Thus, I'd say both trials lend support, and so do those analyses, to the possibility that ACACIA succeeds. On the remaining questions, I share your view — it's somewhat too soon to make guesses about labeling or REMS, that sort of thing. Stuart, is there anything you want to add?
Stuart Kupfer
executiveHonestly, the single point I'd mention would be the safety and tolerability data from SEQUOIA in obstructive HCM. Specifically, aficamten shows a shallow exposure-response relationship, has a fairly brief half-life, and demonstrates a very steady PK profile. In my view, each of those factors plays a role in the tolerability we saw for obstructive HCM, and in the expectation that this will extend to nonobstructive HCM.
Robert Blum
executiveThis wasn't something you requested, but I want to mention it anyway: in Cohort 4 of REDWOOD's Phase II, the effect changes we observed were of such a large magnitude that they give us confidence — should that carry over into Phase III — that we ought to expect a favorable result for ACACIA-HCM. But there's something else, and please keep it firmly in mind: those patients move into FOREST. FOREST is open-label, and before this year ends, you'll be able to see what we are already observing among patients with nHCM who transitioned into FOREST, and that bolsters our confidence regarding what ACACIA can be expected to deliver next year. So our optimism about ACACIA remains quite strong.
John Gionco
analystJohn Gionco here, filling in for Serge today. I just wanted to revisit omecamtiv and the COMET trial; it sounds as though you've been receiving encouraging responses from investigators and KOLs. I was hoping to get a sense of how enrollment is progressing against your own internal projections, given that you're heading toward wrapping up enrollment next year.
Robert Blum
executiveStuart, would you like to address that?
Stuart Kupfer
executiveAbsolutely. Yeah. Like we mentioned earlier during today's call and in a press release, enrollment for the COMET-HF trial remains on schedule. Our goal here — this study involves 1,800 patients, which is under 1/4 the size of GALACTIC. That definitely simplifies things when it comes to operational scope; that said, the population we're dealing with is more severe. So our focus is a narrower subgroup of patients who have HFrEF. Even so, we still intend to finish enrollment before next year ends. Site activations are underway, with the majority already done in the U.S., and we're also on schedule for activating sites throughout Europe. So everything is proceeding as expected.
Robert Blum
executiveOne key point about this study is that it isn't up against a large group of other trials recruiting the same patients. We think this patient group isn't served well by what's currently the standard of care, nor by other treatments under investigation. Rather, we're extending a set of evidence in which we already observed, in GALACTIC, a very strong treatment effect among these patients, and our aim now is simply to verify that in the upcoming trial. So in our view, that's adding to the momentum behind the study.
Mazahir Alimohamed
analystThis is Mazi, sitting in for Roanna. Obviously, just a single question from our side. So, looking at it through the lens of cardiac myosin biology, as you move aficamten forward into additional HCM phenotypes and work on developing ulacamten for HFpEF, given this unique mechanism, could you walk us through the main differentiating factors, how these myosin inhibitors are distinct from one another, and the way they engage with sarcomere function?
Robert Blum
executiveSure. There's no one better suited to field that question than Fady Malik.
Fady Malik
executiveOkay, so it's genuinely fascinating — looking at the myosin motor protein now, more than 20 years on, we have found 3 separate binding sites where small molecule modulators can act on this protein. One location is where aficamten attaches; a second location is where omecamtiv mecarbil and mavacamten attach; and finally, CK-586, or ulacamten, attaches at a third location. And every one of these has its own distinct impact on — regarding the way they influence motor function within the sarcomere, as you could put it. I won't truly get into the specifics and particulars here. But those distinctions, I believe, as we might be observing in the clinic, produce distinctions in their profiles. And I believe it remains a bit early to understand precisely how they vary and which one might be favored. But there are, I believe, distinctions that are starting to appear. With ulacamten, we observe possibly a less steep reduction in ejection fraction, a less steep PK/PD curve than even aficamten. And we believe the reversibility of both compounds is not merely a characteristic of the compound itself, but also possibly the mechanism by which they bind. So I would say keep watching. I hope at some point to write a paper that lays out all the various biology and how it connects to clinical.
Ash Verma
analystI'd like to ask about this late-cycle meeting being moved from June to September — did that happen because of the 3-month PDUFA extension you got earlier? Or is it something separate that could now ripple through and affect your PDUFA date? What I'm trying to figure out is whether a September late-cycle meeting leaves FDA with a big enough runway to wrap up the remaining review work before the deadline.
Robert Blum
executiveYes. As we mentioned in the scripted comments, our view is that the change in timing for the late-cycle meeting lines up with the PDUFA date extension, and nothing suggests to us that there's anything else going on. Based on the interactions we've had with FDA in the interim, we believe we should still treat this as a hopeful approval in line with the PDUFA date. There's no reason to think otherwise.
Robert Blum
executiveThanks, operator, and I want to thank everyone who joined us on today's call. We're grateful for the support you keep giving us; we're grateful for the interest you keep showing in Cytokinetics. There's a great deal happening, and in our view this check-in at the midpoint of the year shows why we remain quite ambitious and hopeful and are planning for success with what we expect could be our first medicine to win potential approval later this year, along with everything that accompanies it. So with that, operator, we're ready to bring the call to a close. Thank you so much.
Operator
operatorAppreciation to the presenters. And everyone, that brings today's conference call to an end. Thanks to each of you for participating. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.